CoA-Z in Pantothenate Kinase-associated Neurodegeneration (PKAN)
A Phase 2 Study of a Vitamin Metabolite for PKAN
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Has a diagnosis of PKAN confirmed by: a) genetic testing confirming 2 pathogenic or likely pathogenic mutations, or (b) typical findings on exam and brain MR imaging with only one pathogenic mutation +/- a second likely pathogenic or VOUS in PANK2, or (c) typical findings on exam and brain MR imaging with a single likely pathogenic or VOUS in PANK2, or (d) be a symptomatic sibling of a proband subject meeting a, b or c.
- Be between 3 months old and 89 years old.
- Be able to take study product by mouth or feeding tube.
- Be willing and able to complete study procedures / telephone visits / blood draws independently, OR have a caregiver / parent willing and able to assist with these tasks.
- Be enrolled or willing to enroll in the PKANready natural history study (eIRB 10832).
- Be resident in North America (US or Canada) for the duration of the trial.
Exclusion Criteria:
- Have had exposure to a putative PANK2 bypass therapeutic agent in the 30 days prior to screening.
- Be concurrently enrolled in another interventional clinical trial.
- Have concurrent medical or other condition expected to preclude completion of study procedures of confound the assessment of clinical and laboratory measures of safety.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CoA-Z dose 1
6 months of CoA-Z at the highest assigned dose followed by 18 months of CoA-Z at dose 2
|
People with PKAN lack a chemical to process or metabolize a certain vitamin in the brain.
CoA-Z is designed to bypass this metabolic defect that causes PKAN.
|
|
Experimental: CoA-Z dose 2
6 months of CoA-Z at the medium assigned dose followed by 18 months of CoA-Z at dose 2
|
People with PKAN lack a chemical to process or metabolize a certain vitamin in the brain.
CoA-Z is designed to bypass this metabolic defect that causes PKAN.
|
|
Experimental: CoA-Z dose 3
6 months of CoA-Z at the lowest assigned dose followed by 18 months of CoA-Z at dose 2
|
People with PKAN lack a chemical to process or metabolize a certain vitamin in the brain.
CoA-Z is designed to bypass this metabolic defect that causes PKAN.
|
|
Placebo Comparator: Placebo
6 months of placebo, followed by 18 months of CoA-Z at dose 2 (medium dose)
|
People with PKAN lack a chemical to process or metabolize a certain vitamin in the brain.
CoA-Z is designed to bypass this metabolic defect that causes PKAN.
The placebo is a strawberry-flavored syrup that looks and tastes like CoA-Z but has no active CoA-Z in it.
|
|
Experimental: Open-label arm
Up to 24 months of CoA-Z at dose 2
|
People with PKAN lack a chemical to process or metabolize a certain vitamin in the brain.
CoA-Z is designed to bypass this metabolic defect that causes PKAN.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Treatment-emergent Adverse Events Assessed Using CTCAE v4.0
Time Frame: 6 months following first dose in double-blind phase
|
Safety will be measured using the number of treatment-emergent adverse events (both AE and SAE) by treatment arm.
Counts are adjusted for number of prescription medications at baseline as a measure of baseline disease severity.
|
6 months following first dose in double-blind phase
|
|
Number of Treatment-emergent Clinically Significant Laboratory Abnormalities on Complete Blood Count.
Time Frame: 6-month randomized, double-blind, placebo-controlled phase
|
Safety will be assessed by measuring the number of treatment-emergent clinically significant laboratory abnormalities on Complete Blood Count.
Clinical significance will be determined by Medical Safety Monitor and Clinical Investigators.
|
6-month randomized, double-blind, placebo-controlled phase
|
|
Number of Treatment-emergent Clinically Significant Laboratory Abnormalities on Comprehensive Metabolic Profile.
Time Frame: 6-month randomized, double-blind, placebo-controlled phase
|
Safety will be assessed by measuring the number of treatment-emergent clinically significant laboratory abnormalities on Comprehensive Metabolic Profile by collection month.
Clinical significance will be determined by Medical Safety Monitor and Clinical Investigators.
|
6-month randomized, double-blind, placebo-controlled phase
|
|
Number of Participants Retained in Each Arm.
Time Frame: 6 month randomized, double-blind, placebo-controlled period
|
Tolerability will be assessed by measuring the number of participants retained in each arm over the course of the study.
|
6 month randomized, double-blind, placebo-controlled period
|
|
Mean Percent of Study Product Consumed.
Time Frame: 6-month randomized, double-blind, placebo-controlled phase
|
Tolerability will be assessed by adherence to the study product regimen arm at each follow-up time point.
|
6-month randomized, double-blind, placebo-controlled phase
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CoASY mRNA Expression
Time Frame: Up to 6 months after first dose
|
Average relative CoASY gene expression, measured as the ratio to baseline of 1 / (2^[COASY Ct - 18s Ct]), where Ct = cycle time and 18s is a housekeeping gene.
Values >1 reflect higher expression.
|
Up to 6 months after first dose
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Penelope Hogarth, M.D., Oregon Health and Science University
- Principal Investigator: Susan J Hayflick, MD, Oregon Health and Science University
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Neurodegenerative Diseases
- Movement Disorders
- Heredodegenerative Disorders, Nervous System
- Basal Ganglia Diseases
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Neuroaxonal Dystrophies
- Pantothenate Kinase-Associated Neurodegeneration
Other Study ID Numbers
Other Study ID Numbers
- IRB00018782
- R01HD097328 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.